Clinical and laboratory characteristics of 319 patients with SSc, indicating the presence or absence of anti-RNA polymerase III antibodies (univariate analysis).
| Patient Characteristic | RNA Pol III | OR (95% CI) | p | |
|---|---|---|---|---|
| Positive (%) | Negative (%) | |||
| Diffuse cutaneous, n = 112/313 | 16/28 (57) | 96/285 (34) | 2.6 (1.2–5.8) | 0.02 |
| Pulmonary fibrosis, n = 131/298 | 11/28 (39) | 120/270 (44) | 0.8 (0.4–1.8) | 0.60 |
| Pulmonary arterial hypertension, n = 14/289 | 1/26 (4) | 13/263 (5) | 0.77 (0.1–6.1) | 0.80 |
| Scleroderma renal crisis, n = 13/318 | 4/29 (14) | 9/289 (3) | 5.0 (1.4–17.3) | 0.012 |
| Anticentromere, n = 76/313 | 1/28 (4) | 75/285 (26) | 0.10 (0.01–0.78) | 0.027 |
| Anti-topoisomerase I, n = 91/312 | 2/28 (7) | 89/284 (31) | 0.17 (0.04–0.73) | 0.017 |
| Anti-U1-RNP, n = 21/217 | 2/17 (12) | 19/200 (10) | 1.3 (0.3–6.0) | 0.73 |